The company exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a catastrophic 5-year price decline of 99.6%. While the balance sheet shows temporary liquidity strength with a Current Ratio of 3.12 and very low debt, these are overshadowed by negative revenue growth (-18.30% YoY) and negative operating margins. The lack of analyst coverage and a share price hovering near zero indicate a loss of market confidence. Overall, the deterministic health scores and growth metrics suggest a failing business model with minimal recovery probability.